

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1656

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CaPlus enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent
Records Containing Equivalent Chemical Indexing
in CA/CaPlus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:34:55 ON 27 DEC 2009

=> File MEDLINE, SCISEARCH, LIFESCI, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE,
BIOTECHNO, WPIDS
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 17:35:05 ON 27 DEC 2009

FILE 'SCISEARCH' ENTERED AT 17:35:05 ON 27 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'LIFESCI' ENTERED AT 17:35:05 ON 27 DEC 2009
COPYRIGHT (C) 2009 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 17:35:05 ON 27 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:35:05 ON 27 DEC 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 17:35:05 ON 27 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 17:35:05 ON 27 DEC 2009
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2009)

FILE 'ESBIODBASE' ENTERED AT 17:35:05 ON 27 DEC 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 17:35:05 ON 27 DEC 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:35:05 ON 27 DEC 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> S (ompt protease or protease VII) (P) (acth or motilin or (calcitonin precursor))
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'VII' (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'VII' (P) '
L1 9 (OMPT PROTEASE OR PROTEASE VII) (P) (ACTH OR MOTILIN OR (CALCITONIN PRECURSOR))

=> S ((ompt protease) or (protease VII)) (P) (acth or motilin or (calcitonin precursor))
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED ')' (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED ')' (P) '

L2 9 ((OMPT PROTEASE) OR (PROTEASE VII)) (P) (ACTH OR MOTILIN OR (CALCITONIN PRECURSOR))

=> duplicate
 ENTER REMOVE, IDENTIFY, ONLY, OR (?) : remove
 ENTER L# LIST OR (END) : 12
 DUPLICATE PREFERENCE IS 'MEDLINE, SCISEARCH, LIFESCI, BIOSIS, EMBASE, HCAPLUS, ESBIOBASE, WPIDS'
 KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N) : n
 PROCESSING COMPLETED FOR L2
 L3 2 DUPLICATE REMOVE L2 (7 DUPLICATES REMOVED)

=> d l3 1-2 bib ab

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 AN 2005:300594 HCAPLUS
 DN 142:368184
 TI Production of biol. active polypeptides by the proteolysis of recombinant synthetic polypeptide precursors by the OmpT protease variants
 IN Okuno, Kazuaki; Yabuta, Masayuki
 PA Daiichi Suntory Pharma Co., Ltd., Japan
 SO PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030956	A1	20050407	WO 2004-JP14704	20040929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004276687	A1	20050407	AU 2004-276687	20040929
	CA 2540446	A1	20050407	CA 2004-2540446	20040929
	EP 1674567	A1	20060628	EP 2004-773628	20040929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004014611	A	20061107	BR 2004-14611	20040929
	CN 1860226	A	20061108	CN 2004-80028525	20040929
	KR 2006089724	A	20060809	KR 2006-705984	20060327
	US 20070077617	A1	20070405	US 2006-573821	20060328
FRAI	JP 2003-342183	A	20030930		
	WO 2004-JP14704	W	20040929		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The proteolytic method for producing biol. active polypeptides (ACTH (1-24), motilin or calcitonin) from recombinant synthetic precursor polypeptides or fusion proteins by using OmpT protease mutants has been developed. The synthetic precursor polypeptides or fusion proteins (22 .apprx. 45 a.a. (amino acid)) have been designed according to the substrate specificities of the OmpT protease mutants. Synthetic substrate polypeptides have Arg or Lys at P1 site and the a.a. other than Asp, Glu or Pro at the P1' site. The substrate polypeptides have one, two or serial three basic a.a. in the

P10 .apprx. P3, P10 .apprx. P3' or P10 .apprx. P5' (more specifically in the P5 .apprx. P3 site), however the sites P6 and P4 are excluded if only one basic a.a. in the sequence. The fusion protein substrates with protection peptide having C-terminal Arg or Lys have N-terminal a.a. such as Phe, Ala, Ser, Cys or Tyr and the other a.a. excluding Asp, Glu and Pro. These preferred P5 .apprx. P1 sequence and P7 .apprx. P1 sequence in the synthetic precursor polypeptides or fusion proteins are Arg-Arg-Arg-Ala-Arg and Asp-Ala-Arg-Arg-Arg-Ala-Arg, resp. Introduction of acidic a.a. typically Asp to the P3 site can repress the digestion by the OmpT proteases. The OmpT protease variants that can be used in the proteolysis system have a.a. variation at the 97th position. The 97th a.a. is Leu, Met or His and the other a.a. including Ala, Phe, Ser, Thr, Cys, Asn, Gln, and Glu. The vector encoding the fusion substrate protein containing human glucagon, motilin, ACTH or calcitonin was designed to satisfy the structural condition claimed above and expressed in the inclusion body of E. coli and the cleaving of biol. active peptides from the substrate fusion proteins by the recombinant OmpT protease variant was demonstrated. The performance of the coexpression system of the substrate fusion protein and OmpT protease variant in the biol. active peptide generation was also demonstrated.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 2
AN 2004028684 MEDLINE
DN PubMed ID: 14711628
TI Utilization of Escherichia coli outer-membrane endoprotease OmpT variants as processing enzymes for production of peptides from designer fusion proteins.
AU Okuno Kazuaki; Yabuta Masayuki; Ooi Toshihiko; Kinoshita Shinichi
CS Institute for Medicinal Research and Development, Daiichi Suntary Pharma Co., Ltd., Akaiwa, Chiyoda-machi, Ohra-gun, Gunma 370-0503, Japan..
SO Applied and environmental microbiology, (2004 Jan) Vol. 70, No. 1, pp. 76-86.
Journal code: 7605801. ISSN: 0099-2240.
Report No.: NLM-PMC321264.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200404
ED Entered STN: 21 Jan 2004
Last Updated on STN: 9 Apr 2004
Entered Medline: 8 Apr 2004
AB Escherichia coli outer-membrane endoprotease OmpT has suitable properties for processing fusion proteins to produce peptides and proteins. However, utilization of this protease for such production has been restricted due to its generally low cleavage efficiency at Arg (or Lys)-Xaa, where Xaa is a nonbasic N-terminal amino acid of a target polypeptide. The objective of this study was to generate a specific and efficient OmpT protease and to utilize it as a processing enzyme for producing various peptides and proteins by converting its substrate specificity. Since OmpT Asp(97) is proposed to interact with the P1' amino acid of its substrates, OmpT variants with variations at Asp(97) were constructed by replacing this amino acid with 19 natural amino acids to alter the cleavage specificity at Arg (P1)-Xaa (P1'). The variant OmpT that had a methionine at this position, but not the wild-type OmpT, efficiently cleaved a fusion protein containing the amino acid sequence -Arg-Arg-Arg-Ala-Arg downward arrow motilin, in which

motilin is a model peptide with a phenylalanine at the N terminus. The OmpT variants with leucine and histidine at position 97 were useful in releasing human adrenocorticotrophic hormone (1-24) (serine at the N terminus) and human calcitonin precursor (cysteine at the N terminus), respectively, from fusion proteins. Motilin was produced by this method and was purified up to 99.0% by two chromatographic steps; the yield was 160 mg/liter of culture. Our novel method in which the OmpT variants are used could be employed for production of various peptides and proteins.